The closing price of FibroGen Inc (NASDAQ: FGEN) was $2.44 for the day, down -7.58% from the previous closing price of $2.64. In other words, the price has decreased by -$0.2000 from its previous closing price. On the day, 1535326 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of FGEN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.33 and its Current Ratio is at 1.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on August 08, 2023, Downgraded its rating to Underperform and sets its target price to $2 from $4 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’24 when Wettig Thane bought 50,000 shares for $1.91 per share. The transaction valued at 95,470 led to the insider holds 470,178 shares of the business.
Henderson Jeffrey William sold 2,000 shares of FGEN for $2,060 on Sep 01 ’23. The Director now owns 28,866 shares after completing the transaction at $1.03 per share. On Aug 04 ’23, another insider, Henderson Jeffrey William, who serves as the Director of the company, sold 2,000 shares for $1.91 each. As a result, the insider received 3,820 and left with 30,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FGEN now has a Market Capitalization of 241.83M and an Enterprise Value of 158.79M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.63. Its current Enterprise Value per Revenue stands at 1.07 whereas that against EBITDA is -0.61.
Stock Price History:
Over the past 52 weeks, FGEN has reached a high of $20.90, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is 1.8593, while the 200-Day Moving Average is calculated to be 2.0923.
Shares Statistics:
FGEN traded an average of 2.61M shares per day over the past three months and 1.79M shares per day over the past ten days. A total of 98.77M shares are outstanding, with a floating share count of 91.83M. Insiders hold about 7.02% of the company’s shares, while institutions hold 71.22% stake in the company. Shares short for FGEN as of Feb 29, 2024 were 6.52M with a Short Ratio of 2.50, compared to 13.5M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.60% and a Short% of Float of 8.68%.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.52, while EPS last year was -$0.81. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.3 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.03 and -$1.7 for the fiscal current year, implying an average EPS of -$1.29. EPS for the following year is -$0.43, with 3 analysts recommending between $0.69 and -$1.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $41M to a low estimate of $31.89M. As of the current estimate, FibroGen Inc’s year-ago sales were $31.84M, an estimated increase of 14.50% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for FGEN’s current fiscal year. The highest revenue estimate was $172M, while the lowest revenue estimate was $144.92M, resulting in an average revenue estimate of $158.36M. In the same quarter a year ago, actual revenue was $147.75M, up 7.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $169.44M in the next fiscal year. The high estimate is $196M and the low estimate is $147.03M. The average revenue growth estimate for next year is up 7.00% from the average revenue estimate for this year.
